Rationale and design of the PACE HFpEF trial: Physiologic accelerated pacing as a holistic treatment of heart failure with preserved ejection fraction.

The Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF) trial of sacubitril-valsartan showed a trend toward improvement in the composite primary endpoint, which was driven by HF events, but the subgroup analysis revealed that only patients with a median LVEF of 57% or lower derived this benefit. 23 , 24 Treatment with sacubitril-valsartan as compared with valsartan alone did not provide patients with an improvement in quality of life.

also in 53,322 other papers